内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Lancet Diab & Endo：预测糖尿病风险或有新帮手

2014-01-24 孙云 编译 医学论坛网

预测糖尿病风险果糖胺糖化白蛋白
关注

一项美国研究显示，果糖胺和糖化白蛋白与糖尿病及其微血管病变的发生之间呈强相关，且对预后的预测价值堪与糖化血红蛋白(HbA1C)相媲美。文章1月15日在线发表于《柳叶刀·糖尿病与内分泌学》(Lancet Diabetes Endocrinol)杂志。 该研究纳入11348名无糖尿病受试者和958例糖尿病患者。结果显示，果糖胺、糖化白蛋白水平超过第95%分位数者发生糖尿病的风险比(HR)分别为4.9

一项美国研究显示，果糖胺和糖化白蛋白与糖尿病及其微血管病变的发生之间呈强相关，且对预后的预测价值堪与糖化血红蛋白(HbA1C)相媲美。文章1月15日在线发表于《柳叶刀·糖尿病与内分泌学》(Lancet Diabetes Endocrinol)杂志。

该研究纳入11348名无糖尿病受试者和958例糖尿病患者。结果显示，果糖胺、糖化白蛋白水平超过第95%分位数者发生糖尿病的风险比(HR)分别为4.96和6.17。果糖胺、糖化白蛋白与视网膜病变之前呈强相关，且这两个检测指标对慢性肾脏病的预测价值与HbA1C相似。

原文出处：

Elizabeth Selvin;Andreea M Rawlings;Morgan Grams;Ronald Klein;A Richey Sharrett;Michael Steffes;Josef Coresh.Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.The Lancet Diabetes & Endocrinology,15 January 2014,doi:10.1016/S2213-8587(13)70199-2

          

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827689, encodeId=671a182e689dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jun 16 09:08:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636801, encodeId=93fe163680172, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Mar 29 08:08:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7219, encodeId=6d16e219ed, content=非常重要和有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa6680472, createdName=horror2001, createdTime=Wed Feb 05 23:16:00 CST 2014, time=2014-02-05, status=1, ipAttribution=)]
    2014-06-16 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1827689, encodeId=671a182e689dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jun 16 09:08:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636801, encodeId=93fe163680172, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Mar 29 08:08:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7219, encodeId=6d16e219ed, content=非常重要和有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa6680472, createdName=horror2001, createdTime=Wed Feb 05 23:16:00 CST 2014, time=2014-02-05, status=1, ipAttribution=)]
    2014-03-29 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827689, encodeId=671a182e689dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jun 16 09:08:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636801, encodeId=93fe163680172, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Mar 29 08:08:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7219, encodeId=6d16e219ed, content=非常重要和有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa6680472, createdName=horror2001, createdTime=Wed Feb 05 23:16:00 CST 2014, time=2014-02-05, status=1, ipAttribution=)]
    2014-02-05 horror2001

    非常重要和有意义的研究

    0